A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER)
Study Identifier:
CLI-06001AA1-04
ClinicalTrials.gov Identifier:
EudraCT Identifier:
Study Contact Information:
N/A
Active, not recruiting
Study Details
Medical Condition
- Chronic Obstructive Pulmonary Disease
Study Drug
- Drug: Experimental: CHF6001 1600µg
- Drug: Experimental: CHF6001 3200µg
- Drug: Placebo
Date
Jul 2021 - Dec 2025
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 40+ years
Requirements Information
Healthy Volunteers
No
Protocol Summary
The purpose of the study is to evaluate the efficacy and safety of two doses of CHF6001 (Tanimilast), as add-on to maintenance triple therapy in the target patient population.
Study Locations
Location
Status
Location
Chiesi Clinical Trial - Site 840402
Sheffield, Alabama, United States, 35660-4020
Status
N/A
Location
Chiesi Clinical Trial - Site 840480
Northridge, California, United States, 91324-6200
Status
N/A
Location
Chiesi Clinical Trial - Site 840487
Cutler Bay, Florida, United States, 33189-1230
Status
N/A
Location
Chiesi Clinical Trial - Site 840404
Hollywood, Florida, United States, 33021
Status
N/A
Location
Chiesi Clinical Trial - Site 840407
Miami, Florida, United States, 33144-2100
Status
N/A
Location
Chiesi Clinical Trial - Site 840444
Miami, Florida, United States, 33144
Status
N/A